Savient Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:SVNTQ)

$0.0019 0.00 (0.00 %)
(As of 12/13/2017 08:00 AM ET)
Previous Close$0.00
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average Volume340,036 shs
Market Capitalization$139,409.00
P/E RatioN/A
Dividend YieldN/A
Beta1.8

About Savient Pharmaceuticals (OTCMKTS:SVNTQ)

Savient Pharmaceuticals logoSavient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.

Receive SVNTQ News and Ratings via Email

Sign-up to receive the latest news and ratings for SVNTQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorHealthcare
SymbolOTCMKTS:SVNTQ
CUSIPN/A
Phone+1-732-4189300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares73,370,000

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Frequently Asked Questions

What is Savient Pharmaceuticals' stock symbol?

Savient Pharmaceuticals trades on the OTCMKTS under the ticker symbol "SVNTQ."

Who are some of Savient Pharmaceuticals' key competitors?

How do I buy Savient Pharmaceuticals stock?

Shares of Savient Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Savient Pharmaceuticals' stock price today?

One share of Savient Pharmaceuticals stock can currently be purchased for approximately $0.00.

How big of a company is Savient Pharmaceuticals?

Savient Pharmaceuticals has a market capitalization of $139,409.00.

How can I contact Savient Pharmaceuticals?

Savient Pharmaceuticals' mailing address is 1 Tower Center Blvd, EAST BRUNSWICK, NJ 08816-1145, United States. The biopharmaceutical company can be reached via phone at +1-732-4189300.


MarketBeat Community Rating for Savient Pharmaceuticals (SVNTQ)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Savient Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Earnings History and Estimates Chart

Earnings by Quarter for Savient Pharmaceuticals (OTCMKTS:SVNTQ)

Savient Pharmaceuticals (OTCMKTS SVNTQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2013Q2 2013($0.31)($0.35)$5.84 million$6.10 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.31)($0.34)$5.65 million$4.70 millionViewN/AView Earnings Details
3/19/2013Q4 2012($0.44)($0.39)$6.18 million$4.95 millionViewN/AView Earnings Details
11/8/2012Q312($0.45)($0.56)$5.87 million$4.91 millionViewN/AView Earnings Details
8/8/2012($0.45)($0.23)ViewN/AView Earnings Details
5/9/2012($0.49)($0.49)ViewN/AView Earnings Details
11/3/2011($0.38)($0.39)ViewN/AView Earnings Details
8/4/2011($0.28)($0.43)ViewN/AView Earnings Details
5/5/2011($0.31)($0.19)ViewN/AView Earnings Details
2/25/2011($0.26)$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Savient Pharmaceuticals (OTCMKTS:SVNTQ)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Savient Pharmaceuticals (OTCMKTS SVNTQ) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Savient Pharmaceuticals (OTCMKTS:SVNTQ)

Savient Pharmaceuticals (OTCMKTS SVNTQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2013Louis FerrariCEOSell1,020$0.57$581.40View SEC Filing  
2/4/2013Louis FerrariCEOSell62,200$1.01$62,822.00View SEC Filing  
2/4/2013Philip K YachmetzSVPSell30,500$1.01$30,805.00View SEC Filing  
2/4/2013Richard CrowleyEVPSell48,900$1.03$50,367.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Savient Pharmaceuticals (OTCMKTS SVNTQ) News Headlines

Source:
No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Savient Pharmaceuticals (OTCMKTS:SVNTQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Savient Pharmaceuticals (OTCMKTS SVNTQ) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.